| Literature DB >> 26970938 |
Jérôme Holtzmann1, Raphaëlle Richieri2, Ghassen Saba3, Najib Allaïli4, Rémy Bation5, Fanny Moliere6, Isabel Nieto4, Frank Bellivier4, Djamila Bennabi7, Maxime Bubrovszky8, Vincent Camus9, Thomas Charpeaud10, Pierre Courvoisier11, Frédéric Haesebaert5, Olivier Doumy12, Philippe Courtet6, Wissam El-Hage9, Marion Garnier10, Thierry d'Amato5, Christophe Lançon2, Marion Leboyer3, Pierre-Michel Llorca10, Guillaume Vaiva8, Thierry Bougerol11, Bruno Aouizerate12, Emmanuel Haffen7.
Abstract
The most largely used definition of the treatment-resistant depression relies on the failure of two successive trials of antidepressant treatment at an adequate dose and duration. The absence of response to previous antidepressant treatments should be assessed using specific and appropriate clinical instruments enabling a correct staging of the therapeutic resistance. A wide range of socio-demographic and clinical factors (i.e. psychiatric/somatic comorbidities) are classically associated with the therapeutic resistance. The aim of the treatment of major depression is to achieve a complete clinical remission. The presence of residual symptoms increases the risk for the subsequent occurrence of relapses and recurrences, hence facilitating the development of therapeutic resistance. The treatment-resistant depression has a deleterious impact on the social, familial or professional functioning, thereby leading to an impaired quality of life with serious socioeconomic consequences and costs.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26970938 DOI: 10.1016/j.lpm.2016.02.002
Source DB: PubMed Journal: Presse Med ISSN: 0755-4982 Impact factor: 1.228